Table 4.
Variables analyses for prediction of mortality in the study patients
| Univariate | Multivariate | |||||
|---|---|---|---|---|---|---|
| Characteristics | P | HR | 95% CI | P | HR | 95% CI |
| Age | < 0.001 | 1.035 | 1.018–1.052 | 0.034 | 1.022 | 1.002–1.044 |
| Male/Female | 0.011 | 1.563 | 1.106–2.210 | 0.945 | 0.976 | 0.493–1.934 |
| Smoking history | 0.032 | 1.463 | 1.034–2.071 | 0.110 | 1.758 | 0.879–3.513 |
| Positive autoimmune Ab | < 0.001 | 0.498 | 0.347–0.714 | 0.433 | 0.804 | 0.467–1.386 |
| First line treatment | 0.549 | |||||
| Systemic corticosteroid | 1 | – | ||||
| Antifibrotics | 1.417 | 0.453–4.432 | ||||
| Emphysema from HRCT | 0.514 | 1.132 | 0.780–1.642 | |||
| FVC (%) | < 0.001 | 0.964 | 0.954–0.975 | < 0.001 | 0.970 | 0.955–0.984 |
| DLCO (%) | < 0.001 | 0.978 | 0.969–0.988 | 0.051 | 0.988 | 0.976–1.000 |
| ILD exacerbation (yes/no) | 0.003 | 1.654 | 1.180–2.317 | 0.001 | 2.074 | 1.366–3.148 |
| ILD type | < 0.001 | 0.039 | ||||
| IPF | 1 | 1 | ||||
| IPAF | 0.008 | 0.470 | 0.269–0.821 | 0.047 | 0.436 | 0.192–0.990 |
| CTD-ILD | < 0.001 | 0.235 | 0.135–0.410 | 0.026 | 0.401 | 0.179–0.898 |
Abbreviations: Ab antibody, CTD-ILD connective tissue disease-related interstitial lung disease, DLCO Diffusing capacity of the lungs for carbon monoxide, FVC forced vital capacity, HRCT high-resolution computed tomography scan, ILD interstitial lung disease, IPAF interstitial pneumonia with autoimmune features, IPF idiopathic pulmonary fibrosis